Relay Therapeutics IncRLAY
ASignal's systematic analysis rates RLAY as Bearish.
Reflects the latest available analysis · analyzed Sep 3, 2026
The case on RLAY
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $910.93M in total cash
- Low debt-to-equity ratio of 0.03x indicating minimal leverage risk
- High current and quick ratios (18.27x and 17.93x) suggesting strong short-term liquidity
- RSI near oversold territory (37.8), potentially indicating downside exhaustion
- Negative MACD histogram and MACD below signal line signaling bearish momentum
- Negative price momentum (-0.06) and trading below both SMA20 and SMA50
- Severely negative operating margin (-25,949.72%) and negative free cash flow
- Extremely high valuation metrics: EV/Revenue at 306.86x, P/S at 391.91x
- Revenue growth declining YoY by 48.3%
- Negative ROE (-36.77%) and negative return on assets (-22.88%)
See the full verdict on RLAY
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes RLAY
Most investors never get a second opinion, let alone several. ASignal runs RLAY past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.